New and Emerging Drug Molecules Against Obesity

Pharmacological inhibition to examine the role of DGAT1 in dietary lipid absorption in rodents and humans

(2013) Benjamin S. Maciejewski et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Association of All-Cause Mortality With Overweight and Obesity Using Standard Body Mass Index Categories

(2013) Katherine M. Flegal et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)

(2013) Caroline M. Apovian et al.   Obesity

Impact of Obesity and the Obesity Paradox on Prevalence and Prognosis in Heart Failure

(2013) Carl J. Lavie et al.   JACC-Heart Failure

Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study

(2012) Patrick M. O'Neil et al.   Obesity

Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study

(2011) W Timothy Garvey et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

Calorie Restriction-like Effects of 30 Days of Resveratrol Supplementation on Energy Metabolism and Metabolic Profile in Obese Humans

(2011) Silvie Timmers et al.   Cell Metabolism

New Drug Targets for the Treatment of Obesity

(2011) A G Powell et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial

(2011) Meredith C. Fidler et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Multiple-Dose Safety, Pharmacokinetics, and Pharmacodynamics of the μ-Opioid Receptor Inverse Agonist GSK1521498

(2011) Pradeep J. Nathan et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial

(2011) Kishore M Gadde et al.   LANCET

Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)

(2011) David B. Allison et al.   Obesity

The anti-angiogenic herbal composition Ob-X fromMorus alba,Melissa officinalis, andArtemisia capillarisregulates obesity in genetically obese ob/ob mice

(2011) Michung Yoon et al.   PHARMACEUTICAL BIOLOGY

Acute effects of betahistine hydrochloride on food intake and appetite in obese women: a randomized, placebo-controlled trial

(2010) Asem H Ali et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

Central and Peripheral Molecular Targets for Antiobesity Pharmacotherapy

(2010) M A Valentino et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Neuropsychiatric Adverse Effects of Centrally Acting Antiobesity Drugs

(2010) Pradeep J. Nathan et al.   CNS Neuroscience & Therapeutics

A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study

(2010) L J Aronne et al.   INTERNATIONAL JOURNAL OF OBESITY

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

(2010) Frank L Greenway et al.   LANCET

Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management

(2010) Steven R. Smith et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects

(2010) W. Philip T. James et al.   NEW ENGLAND JOURNAL OF MEDICINE

Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR-BMOD Trial

(2010) Thomas A. Wadden et al.   Obesity

Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders

(2009) David J. Heal et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Potent and Selective Agonism of the Melanocortin Receptor 4 With MK-0493 Does Not Induce Weight Loss in Obese Human Subjects: Energy Intake Predicts Lack of Weight Loss Efficacy

(2009) R Krishna et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Orlistat-Associated Adverse Effects and Drug Interactions

(2009) Theodosios D Filippatos et al.   DRUG SAFETY

Tesofensine – a novel potent weight loss medicine

(2009) Sheila A Doggrell   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Obesity and Cardiovascular Disease

(2009) Carl J. Lavie et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

(2009) Arne Astrup et al.   LANCET

Angiogenesis and development of adipose tissue

(2009) V. Christiaens et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Weight Loss, HbA1cReduction, and Tolerability of Cetilistat in a Randomized, Placebo-controlled Phase 2 Trial in Obese Diabetics: Comparison With Orlistat (Xenical)

(2009) Peter Kopelman et al.   Obesity

Systematic prevention of overweight and obesity in adults: a qualitative and quantitative literature analysis

(2009) S. Kremers et al.   Obesity Reviews

Population-Based Prevention of Obesity

(2008) Shiriki K. Kumanyika et al.   CIRCULATION

Effect of histaminergic manipulation on weight in obese adults: a randomized placebo controlled trial

(2008) N Barak et al.   INTERNATIONAL JOURNAL OF OBESITY

Lorcaserin, a Novel Selective Human 5-Hydroxytryptamine2C Agonist: in Vitro and in Vivo Pharmacological Characterization

(2008) W. J. Thomsen et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Angiogenesis and obesity

(2007) H. R. Lijnen   CARDIOVASCULAR RESEARCH